During the last decades, new radionuclide-based targeted therapies have emerged as
efficient tools for cancer treatment. Targeted radionuclide therapies (TRTs) are based on a …

The International Commission on Radiation Units and Measurements (ICRU), since its
inception in 1925, has had as its principal objective the development of internationally …

The potential of α-particle emitters to treat cancer has been recognized since the early
1900s. Advances in the targeted delivery of radionuclides and radionuclide conjugation …

Purpose: The extreme radiotoxicity of Auger electrons and their exquisite capacity to
irradiate specific molecular sites has prompted scientists to extensively investigate their …

Purpose Minimal residual disease (MRD) and genetic abnormalities are important risk
factors for outcome in acute lymphoblastic leukemia. Current risk algorithms dichotomize …

Recurrence in hepatocellular carcinoma (HCC) after conventional treatments is a crucial
challenge. Despite the promising progress in advanced targeted therapies, HCC is the …

Bioconjugates used in internal radiotherapy exhibit heterogeneous distributions in organs
and tumors, implying a risk of nonuniform dose distribution in therapeutic applications using …

Auger electrons can be highly radiotoxic when they are used to irradiate specific molecular
sites. This has spurred basic science investigations of their radiobiological effects and …

Radiation-induced bystander effects have been implicated in contributing to the growth
delay of disseminated tumor cells (DTC) caused by 223RaCl2, an alpha particle–emitting …

Alpha-particle radiopharmaceutical therapy (αRPT) is currently enjoying increasing attention
as a viable alternative to chemotherapy for targeting of disseminated micrometastatic …